Lates News

Recently, the oxytocin injection and octreotide acetate injection produced by Shangyao First Biochemical, a subsidiary of Shanghai Pharmaceutical, have been approved for listing in the Philippines with drug registration certificates. Oxytocin is used for induced labor and was approved domestically in 1994; octreotide acetate is used to treat acromegaly and was approved domestically in 2006, passing generic drug consistency evaluation in 2022. Both drugs were listed in the Philippines without additional research and development costs, only registration fees of about 50,000 yuan. In 2024, sales of oxytocin in the Philippine market amounted to 970,000 US dollars. This approval will benefit the expansion of overseas markets, but sales are uncertain due to factors such as policy and exchange rates.